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Cancer is the second leading cause of death in US. Despite the emergence of new, tar-
geted agents, and the use of various therapeutic combinations, none of the available
treatment options are curative in patients with advanced cancer. Epigenetic alterations are
increasingly recognized as valuable targets for the development of cancer therapies. DNA
methylation at the 5-position of cytosine, catalyzed by DNA methyltransferases (DNMTs), is
the predominant epigenetic modification in mammals. DNMT1, the major enzyme respon-
sible for maintenance of the DNA methylation pattern is located at the replication fork
and methylates newly biosynthesized DNA. DNMT2 orTRDMT1, the smallest mammalian
DNMT is believed to participate in the recognition of DNA damage, DNA recombination,
and mutation repair. It is composed solely of the C-terminal domain, and does not pos-
sess the regulatory N-terminal region.The levels of DNMTs, especially those of DNMT3B,
DNMT3A, and DNMT3L, are often increased in various cancer tissues and cell lines, which
may partially account for the hypermethylation of promoter CpG-rich regions of tumor sup-
pressor genes in a variety of malignancies. Moreover, it has been shown to function in
self-renewal and maintenance of colon cancer stem cells and need to be studied in sev-
eral cancers. Inhibition of DNMTs has demonstrated reduction in tumor formation in part
through the increased expression of tumor suppressor genes. Hence, DNMTs can poten-
tially be used as anti-cancer targets. Dietary phytochemicals also inhibit DNMTs and cancer
stem cells; this represents a promising approach for the prevention and treatment of many
cancers.
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INTRODUCTION
DNA methylation and histone modifications are two key play-
ers in epigenetic regulation of gene expression in mammalian
cells. Epigenetic modifications play an important role in multi-
stage carcinogenesis (1, 2). Extensive analysis of different types
of human cancer has revealed that epigenetic alteration of the
genome plays a causal role in tumorigenesis. Analysis of epige-
netic alterations in tissue samples, together with the histological
features of each cancer may aid the understanding of the molec-
ular background of histological heterogeneity in human cancers.
DNA methylation, a covalent chemical modification resulting in
addition of a methyl group at the carbon 5 position of the cytosine
ring in CpG dinucleotides, is one of the most consistent and best
known epigenetic events in human cancers. In comparison with
normal cells, human cancer cells exhibit global DNA hypomethy-
lation, which can lead to genomic instability, and specific promoter
hypermethylation of tumor-suppressor genes, which mediates
gene silencing (3). Unlike genetic changes, epigenetic changes can
be reversed by pharmacological intervention. Many studies have
been focused on understanding the structure and functions of
key cellular enzymes that mediate these epigenetic processes and
on subsequently developing small molecule inhibitors that target
these proteins. In addition, epigenetic alterations are increasingly
recognized as valuable targets for the development of cancer
therapies.
Methylation of DNA at 5-position of cytosine, catalyzed by
DNA methyltransferases (DNMTs), is the predominant epige-
netic modification in mammals. Aberrations in methylation play
a causal role in a variety of diseases, including cancer. Recent stud-
ies have established that like mutation, methylation-mediated gene
silencing often leads to tumorigenesis. Paradoxically,genome-wide
DNA hypomethylation may also play a causal role in carcino-
genesis by inducing chromosomal instability and spurious gene
expression. Since methylation does not alter DNA base sequence,
much attention has been focused recently on developing small
molecule inhibitors of DNMTs that can potentially be used as
anti-cancer agents (4). Novel insights provide startling new infor-
mation regarding DNMTs, with respect to their roles in cancer
and the types of proteins they interact with. This information has
forced a new view for the role of DNMTs 1, 2, and 3 (5). In this
study, we have reviewed the updated information for DNMTs as
novel targets for prevention and therapy.
DNA METHYLTRANSFERASES
Methylation of mammalian genomic DNA is catalyzed by DNMTs.
Patterns of DNA methylation are established by the coordinated
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action of the DNMTs and associated factors, such as the polycomb
proteins in the presence of S-adenosyl-methionine that serves as
a methyl donor (5). The mammalian DNMT family includes four
active members: DNMT1, DNMT3A, DNMT3B, and DNMT3L (6,
7). Mammalian DNMTs are responsible for methylation pattern
acquisition during gametogenesis, embryogenesis, and somatic
tissue development (5). DNMT1 is the most abundant DNMT
involved in the maintenance of methylation (8). DNMT3 func-
tions as a de novo methyltransferase and consists of two related
proteins encoded by distinct genes, DNMT3A and DNMT3B (9).
Of special interest is DNMT2, which has the potential to methylate
RNA instead of DNA (10) (Figure 1).
The DNMT1 is the major enzyme responsible for maintenance
of the DNA methylation pattern. DNMT1 is also often referred
to as maintenance methyltransferase, because it is believed to be
the primary enzyme responsible for copying methylation patterns
after DNA replication (8). DNMT1 is located at the replication
fork and methylates newly biosynthesized DNA (4). The mam-
malian DNMTs comprised two regions: a C-terminal catalytic
portion and a large multi-domain N-terminal region of variable
size, which encodes regulatory functions. The C-terminal part is
composed of 500 amino acids that are conserved between C5
DNMTs of eukaryotics and prokaryotics, and harbor the active
center of the enzyme, containing amino acids motifs characteristic
of the cytosine-C5 methyltransferases. The N-terminal region gen-
erally contains 621 amino acids that are not essential for DNMT1
activity (4), but are required for discriminating between hemi-
methylated and unmethylated DNA. The catalytic domains of all
the DNMTs share a common core structure, known as “AdoMet-
dependent methyltransferase.” This domain is involved in both
cofactor binding (motifs I and X) and substrate catalysis (motifs
IV, VI, and VIII). A non-conserved region between motifs VIII
and IX, believed to be the target recognition domain, is involved
in DNA recognition and specificity (Figure 1). DNMT1 is the most
abundant DNMT targeted to replication foci. Three sequences in
the N-terminal region increase the precision in maintenance of
methylation and give the enzyme direct access to the nuclear repli-
cation site: the proliferating cell nuclear antigen (PCNA) binding
domain, the replication foci targeting sequence, and the poly-
bromo homology domain. PCNA is required for DNA replication,
and the DNMT1–PCNA interaction may allow the newly synthe-
sized daughter strands to be rapidly remethylated before being
packaged into chromatin. This tight association of the DNMT1
with the replication machinery allows DNMT1 to bind newly repli-
cated and the naked DNA (11). Without DNMT, some genes may
hinder interaction with the replicating foci. Cell-cycle regulator
p21 can disrupt DNMT–PCNA interaction, suggesting that p21
may negatively regulate methylation by blocking access of DNMT
to PCNA, particularly during DNA damage when p21 protein is
induced. Moreover, p21 can itself inhibit DNMT1 gene expres-
sion. Under experimental conditions, DNMT1 has up to a 50-fold
preference for hemi-methylated DNA substrate and is localized
FIGURE 1 | Schematic representation of the human DNMT1, DNMT2, orTRDMT1 and DNMT3A, 3B, and 3L. The N-terminal contains motifs of interaction
with proteins or DNA. The C-terminal contains the conserved methyltransferases domains. PHD, plant homology domain.
Frontiers in Oncology | Cancer Molecular Targets and Therapeutics May 2014 | Volume 4 | Article 80 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subramaniam et al. DNA methyltransferases and cancer
to the replication foci during S-phase. It is proposed to dupli-
cate DNA methylation patterns in the daughter strands during
DNA replication (12). Mouse models with both alleles of DNMT1
deleted are embryonic lethal at approximately day E9 (13). The
retinoblastoma gene product Rb, another cell-cycle regulator pro-
tein, can bind to DNMT1 and inhibit its methyltransferase activity
during DNA replication in the cell cycle. Loss of functional Rb may
grant DNMT1 free access to the genome, which could allow aber-
rant de novo methylation of CpG. These observations point to a
complicated network of connections between DNMT1 and sev-
eral cellular proteins involved in gene regulation and epigenetic
signaling during cell replication (4).
DNMT2 is the smallest mammalian DNMT and it is now
termed as TRDMT1. It is composed solely of the C-terminal
domain, and does not possess the regulatory N-terminal region.
The structure of DNMT2 suggests that this enzyme participates
in the recognition of DNA damage, DNA recombination, and
mutation repair (14). DNMT2 is a methyltransferase homolog
that methylates cytosine-38 in the anticodon loop of aspartic acid
transfer RNA instead of DNA (15).
DNMT3A and DNMT3B cannot differentiate between
unmethylated and hemi-methylated CpG sites, and they can-
not copy a specific pattern of methylation or contribute to the
maintenance of methylation pattern (16). Because they show no
preference for hemi-methylated DNA, both enzymes appear to
function as de novo methyltransferases (16) and show a dis-
perse distribution throughout the nucleus not associated with
replication sites, even during S-phase (17). This finding suggests
that these DNMTs utilize a different mechanism for accessing
the densely packed chromatin and for interacting with their
target sites that may involve auxiliary factors such as chro-
matin remodeling complexes (18). Mice lacking DNMT3A die
at about 4 weeks of age, whereas DNMT3B knockout induces
embryonic lethality at E14.5–E18.5 (16). Possessing homology to
DNMT3A and DNMT3B, DNMT3L assists the de novo methyl-
transferases by increasing their ability to bind to the methyl
group donor, S-adenosyl-L-methionine, and stimulating their
activity in vivo (19), although DNMT3L has no catalytic activ-
ity itself. DNMT3L homozygous-null mice are viable, whereas
heterozygous embryos derived from homozygous DNMT3L-null
oocytes die around E9 and display impaired maternal methyla-
tion imprints and biallelic expression of imprinted genes nor-
mally expressed only from the allele of paternal origin (20).
Cooperation among different DNMTs is also required in methy-
lating some regions of the genome, particularly repetitive ele-
ments. It is widely speculated that DNMT1 acts in “maintenance”
of methyltransferase during DNA synthesis and that DNMT3A
and DNMT3B act as “de novo” enzymes in development. How-
ever, mounting evidence indicates that DNMT1 may also be
required for de novo methylation of genomic DNA and that
DNMT3A and DNMT3B contribute to maintain methylation
during replication (21).
DNMT3A and DNMT3B are highly expressed in early embry-
onic cells, the stage in which most programed de novo methyla-
tion events occur, are downregulated after differentiation and in
adult somatic tissues, and are overexpressed in tumor cells (22).
DNMT3B has been shown to play a crucial role in incorporating de
novo hypermethylation of promoter CpG islands, a possible mech-
anism for tumor suppressor gene inactivation within human can-
cer cells (22). Another member of the DNMT3 family is DNMT3L,
a regulatory factor for de novo methylation without methylation
capacities (23). Its amino acid sequence is very similar to that
of DNMT3A and DNMT3B but lacks the residues required for
DNMT activity in the C-terminal domain (23). Additional studies
are required for the precise role for DNMT3L.
Recent studies suggest that an interaction between DNMT1
and DNMT3B may be vital for the maintenance of patterns of
DNA methylation in human colon-cancer cells, particularly in
repeat regions and imprinted genes (23). During early embryo-
genesis, de novo DNA methylation is mediated by DNMT3A and
DNMT3B associated with DNMT3L. It has recently been reported
that in the cell, DNMT3A and DNMT3B are tightly associated with
nucleosomes containing methylated DNA (23). Both the direct
interaction of these proteins with the histone tails and the poly-
merization of DNMT3A could contribute to the stable association
of these enzymes with chromatin. The levels of DNMTs, espe-
cially those of DNMT3A and DNMT3B, are often increased in
various cancer tissues and cell lines. This may partially account
for the hypermethylation of promoter CpG-rich regions of tumor
suppressor genes in a variety of malignancies (24).
DNA METHYLTRANSFERASES OVEREXPRESSION AND
CANCER
The human DNMTs 1, 3A, and 3B coordinate mRNA expression
in normal tissues and overexpression in tumors (25). The expres-
sion levels of these DNMTs are reportedly elevated in cancers of
the colon (26), prostate (27), breast (28, 29), liver (30), and in
leukemia (31). The role of altered expression of DNMTs in DNA
hypomethylation and hypermethylation in cancer is uncertain and
may involve changes in mRNA or protein expression. There is
considerable evidence indicating an up-regulation of DNMT1 in
cancer (32, 33). In addition, experimental evidence indicates that
forced overexpression of the murine DNMT1 gene in NIH3T3
cells results in cellular transformation (34). In human fibroblasts,
sustained overexpression of DNMT1 leads to the processive time-
dependent hypermethylation of a number of CpG islands (35).
DNMT1 expression is upregulated following fos overexpression
and appears to play a role in the fos-induced cell transforma-
tion (36). Conversely, reduction of DNMT1 levels appears to have
protective effects. Mice predisposed to colonic polyp formation
(Min mice) develop fewer polyps in a DNMT1 heterozygous
background. Similar results are seen when treated with 5aza-
dC (37). Reduction of DNMT1 through an antisense approach
also blocks tumorigenesis (38–41). Interestingly, deletion of the
DNMT1 gene in a colon cancer cell line (HCT116), while resulting
in slower growth, diminished genomic methylation levels mod-
estly ~20% (42). In particular, aberrant CpG island methylation
was retained suggesting that another methyltransferase maintains
this methylation. Like DNMT1, the aforementioned DNMT3A
and DNMT3B enzymes also appear to be modestly overexpressed
in cancer. Therefore, the balance of all three enzymes and their
accumulative and coordinated effects must be studied (25, 43).
DNMTs and its importance in specific cancers are summarized in
Table 1.
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Table 1 | DNA methyltransferases and its importance in specific cancer.
DNA methyltransferases Importance in specific cancer Reference
DNMT1 Leukemia: upregulated – 5.3-fold expression Mizuno et al. (44)
Gastric cancer – 64.8% localized in the cytoplasm and nuclei Yang et al. (45)
Breast cancer – 16.6% Girault et al. (28)
Hepatocellular carcinoma – 100% Nagai et al. (46)
Pancreatic cancer – highly expressed – Gli target gene He et al. (47)
Colon cancer – highly expressed Robertson et al. (25)
Glioblastoma – overexpressed Rajendran et al. (48)
DNMT2 or TRDM T1 Hepatocellular carcinoma – reduced expression Saito et al. (49)
Colorectal and stomach cancers – lower mRNA expression Kanai et al. (50)
DNMT3A Acute myeloid leukemia – 22.1% mutations and affect translation Ley et al. (51)
Gastric cancer – 70.4% localized in the cytoplasm Yang et al. (45)
Breast cancer – 14% Girault et al. (28)
Hepatocellular carcinoma – 60% Nagai et al. (46)
Pancreatic cancer – highly expressed – regulated by Gli1 He et al. (47)
Colon cancer – highly expressed Robertson et al. (25)
DNMT3B Leukemia: upregulated – 11.7-fold expression Mizuno et al. (44)
Gastric cancer – 51.9% localized in the cytoplasm Yang et al. (45)
Breast cancer – 81.8% poor prognosis Girault et al. (28)
Breast cancer cell lines-hypermethylation defect resulted in
aberrant – overexpression DNMT activity
Roll et al. (52)
Hepatocellular carcinoma (60%) and mRNA levels high Nagai et al. (46)
Colon cancer – highly expressed Robertson et al. (25), Ibrahim et al. (53)
Prostate cancer – overexpressed Kobayashi et al. (54)
Glioblastoma – overexpressed Rajendran et al. (48)
DNMT3L Cervical cancer – promising biomarker Gokul et al. (55)
Embryonal carcinoma – novel biomarker Minami et al. (56)
COLON CANCER
Colorectal cancer is the second leading cause of death in the United
States and is a major health problem globally (57). The lifetime
risk of developing colorectal cancer in both men and women is
about 1 in 20 (5.1%) (58). Colorectal cancer affects over 146,970
individuals yearly, and accounts for around 49,920 deaths (59).
The American Cancer Society (ACS) estimated 96,830 new cases
(48,450 men and 48,380 women) would be diagnosed with colon
cancer during 2014 and also estimated 50,310 deaths (26,270 men
and 24,040 women) (60–62). Screening for colon cancer can be
done by colonoscopy to find polyps, and removing these polyps at
an early stage can prevent cancer progression. When the polyps
are allowed to persist in the colon for a long time, they may
develop into cancer. Hence, regular colonoscopy is recommended
in the United States for those over 50 years of age (63). Recur-
rence of colon cancer is common, with an estimated 40% of cases
returning within 3–5 years of treatment. Chemotherapeutic com-
pounds currently being used for the treatment of colorectal cancer
include 5-fluorouracil, Oxaliplatin, and Irinotecan hydrochloride
or drug combinations FOLFOX or FOLFIRI. Because conven-
tional therapies, including surgical resection, chemotherapy, and
radiation are often inadequate in treating this disease, new treat-
ment options are critically needed. Despite the emergence of novel
targeted agents and the use of various therapeutic combinations,
no treatment options are available that are curative in patients
with advanced cancer. More recently, the cancer stem-cell con-
cept is gaining importance, because it suggests new approaches
to anti-cancer therapies (64, 65). Cancer tissues are composed
from several heterogeneous cancer cells and a small population
of cancer cells is supposed to have higher tumor-initiating abil-
ity. These higher tumorigenic populations are named “cancer
stem cells (CSCs)” or “cancer initiating cells (CICs).” CSCs/CICs
are defined as small population of cancer cells which has (1)
higher tumor-initiating ability, (2) self-renewal, and (3) differ-
entiation (66–71). CSCs/CICs have been reported to be resistant
to chemotherapy, radiotherapy, and certain molecular targeting
therapies (72); thus, elucidation of the molecular mechanisms of
the maintenance of CSCs/CICs should be useful for establishing
efficient CSC/CIC targeting treatment. Potential markers of col-
orectal cancer stem cells have been proposed, including CD133,
CD166, CD24, CD44, ALDH1, LGR5, and DCLK1 (65, 73–76).
Most recently, Nakanishi and colleagues demonstrated that dou-
blecortin and CaM kinase-like-1 (DCLK1) distinguishes between
tumor and normal stem cells in the intestine. Their studies demon-
strated that specific ablation of DCLK1+ stem cells resulted in
a marked regression of polyps without apparent damage to the
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normal intestine and could be a therapeutic target for colon cancer
(77, 78).
COLON CANCER AND DNMTs
DNMT1 and DNMT3B modulate distinct polycomb-mediated
histone modifications in colon cancer (79). Manipulation of
DNMT1 levels has been used as a tool to study the effect of DNA
hypomethylation on tumorigenesis in several in vivo studies. The
role of DNA methylation in vivo was first explored in the intestine
using the APCMin/+, a commonly used mouse model of intestinal
tumors since it very closely mimics the human familial adeno-
matous polyposis (FAP) condition (80–82). These mice develop
benign intestinal tumors with a rare occurrence of malignant can-
cers (81). Treatment of APCMin/+ mice with the demethylating
agent, 5-aza-2′-deoxycytidine, significantly reduces tumor forma-
tion in the intestine, suggesting that DNA methylation may play an
important role during tumorigenesis (80). Moreover, overexpres-
sion of DNMT3B1 in the APCMin/+ model enhanced colorectal
carcinogenesis and caused tumor suppressor gene methylation
(83). Other studies have also shown that crossing APCMin/+ mice
with DNMT1 hypomorphic mice results in complete suppression
of macroscopic intestinal neoplasia (84). Reduced DNMT1 expres-
sion also affects the frequency of malignant intestinal tumors in
DNA mismatch repair deficient mice (Mlh1−/−) (85, 86).
COLON CANCER STEM CELLS AND DNMTs
Previous studies have reported that hematopoietic stem cell
self-renewal can be abrogated by conditional gene knockout of
DNMT1, while the mature differentiated hematopoietic lineage
is not affected (87). DNMT1 is essential for maintenance of the
leukemia stem cells of bilinear myeloid-B lymphoid leukemia
induced by transduction of c-Myc and Bcl-2 (88). DNMT1
was also shown to be essential for the self-renewal of skin
progenitor cells (89). Most recently, studies have demonstrated
that DNMT1 functions in the maintenance of human colon
CSCs/CICs using the human colon cancer cell line HCT116 and
its DNMT1 somatic knockout variant (DNMT1−/−). The rates
of CSCs/CICs were evaluated by side population (SP) analy-
sis, ALDEFLUOR assay, and expression of CD44 and CD24. SP,
ALDEFLUOR+ and CD44+ and CD24+ (CD44+CD24+) cell
rates were lower in DNMT1−/− cells than in control HCT116 cells.
Since CSCs/CICs have higher tumor-initiating ability than that of
non-CSCs/CICs, the tumor-initiating ability was also addressed
by injecting immune deficient NOD/SCID mice (90). DNMT1−/−
cells showed less tumor-initiating ability than did control HCT116
cells, whereas the growing rate of DNMT1−/− cells showed no
significant difference from that of HCT116 cells both in vitro
and in vivo (90). Similar results were obtained for cells in which
DNMT1 had been transiently knocked-down using gene-specific
siRNAs. These results indicate that DNMT1 is essential for main-
tenance of colon CSCs/CICs and that short-term suppression of
DNMT1 might be sufficient to disrupt CSCs/CICs (90).
PANCREATIC CANCER
Pancreatic cancer is an aggressive malignancy with one of the high-
est mortalities among all cancers. It is the fourth leading cause of
cancer death in the United States with <5% 5-year survival rate.
The lifetime risk of developing pancreatic cancer in both men and
women is about 1 in 79 (1.27%) (91). The ACS estimated that
new cases of 46,420 Americans (23,530 men and 22,890 women)
would be diagnosed with pancreatic cancer during 2014. The ACS
also estimated that 39,590 Americans (20,170 men and 19,420
women) would die of pancreatic cancer in 2014 (60, 62). Despite
advances in molecular pathogenesis, problems such as drug resis-
tance and susceptibility for metastasis make pancreatic cancer a
major unsolved health problem in the United States (92). Unfor-
tunately, pancreatic cancer is a rapidly invasive, metastatic tumor
that is resistant to standard therapies (93). At present, single agent-
based chemotherapy (e.g., gemcitabine) is the mainstay treatment
for metastatic pancreatic adenocarcinoma. Recent data indicate
that in addition to Gemcitabine and a 5-FU plus, a platinum
agent such as Oxaliplatin could be used as a therapeutic para-
digm for early-stage cancer patients (94). However, none of the
available current chemotherapeutic agents have objective response
rates of over 10% (95, 96). The magnitude of this problem man-
dates the need for novel therapeutic agents. Recently, CSCs and
epithelial–mesenchymal transition (EMT)-type cells, which share
molecular characteristics with CSCs, have been postulated to play
critical roles in drug resistance and cancer metastasis in pancre-
atic cancer (97). Recent studies suggest that CD44+CD24+ESA+
(epithelial specific antigen) and ALDH1 could potentially be pan-
creatic cancer stem-cell markers (98, 99). In addition, we have
determined that an identified intestinal stem-cell marker DCLK1
is also expressed in a small proportion of cells in the pancreas and
in pancreatic cancer stem-cell marker (100, 101).
PANCREATIC CANCER AND DNMTs
Aberrant DNA hypermethylation patterns have been observed in
both early- and late-stage human pancreatic tumors (86, 102).
Oghamian et al. hypothesized that reduction in DNA methyla-
tion levels may decrease pancreatic tumor burden in vivo (86).
Mice heterozygous for mutation of APC gene are predisposed
to the development of benign intestinal polyps, whereas mice
homozygous for a mutation in the Trp53 gene develop a wide
range of malignancies, including sarcomas and lymphomas (103).
The combined mutation of APCMin/+and Trp53−/− has been
shown to result in a shift in phenotype with nearly 83% of the
animals developing abnormalities of the exocrine pancreas, of
which 22% also possessed pancreatic acinar cell carcinoma (104,
105). Oghamian et al. also studied the role of DNA methyla-
tion in pancreatic tumorigenesis, using this APCMin/+Trp53−/−
mouse model of exocrine pancreatic cancer and crossed it with
mice carrying hypomorphic alleles of DNMT1. They found that
tumor burden, but not tumor size, is significantly reduced with
decreasing DNMT1 levels, suggesting that DNA methylation is
involved in pancreatic tumorigenesis in this mouse model. Their
detailed analyses also showed that the reduction in tumor burden
is the result of a decrease in both early- and late-stage lesions. In
addition, they observed decreased levels of DNA methylation at
candidate genes in the normal pancreas of DNMT1 hypomorphic
mice (86). Moreover, the expression of DNMT1 protein increased
with the development of pancreatic cancer from normal tissue to
precancerous lesions (PanINs) and to cancer (PDAC) (106–109).
Clinic pathological analyses by Wang and colleagues suggested
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that PDAC patients with higher DNMT1 protein expression had
an overall lower survival rate than those with lower expression.
Moreover, higher DNMT1 expression correlated with advanced
stages of the disease, reflecting the malignancy potential of PDAC
(109). Recent studies examining DNMT mRNA expression in pan-
creatic cancer has also demonstrated that the levels of the three
DNMTs increased with the development of pancreatic cancer from
normal duct to pancreatic intraductal neoplasia and further to
PDAC. In a statistical study with TNM staging and history of
chronic pancreatitis, DNMT3A and DNMT3B, but not DNMT1
expression, correlated with tumor size. Patients with higher levels
of DNMT3A, and/or DNMT3B expression had an overall lower
survival than those with lower levels of expression (110). Fur-
thermore, univariate analysis showed that high expression levels
of DNMTs, in concert with alcohol consumption, tumor dif-
ferentiation, and TNM staging were statistically significant risk
factors. Multivariate analyses showed that high level of DNMT3B
expression and tumor differentiation were statistically significant
independent poor prognostic factors. Their results suggested that
pancreatic carcinogenesis involves an increased mRNA expres-
sion of three DNMTs, and they may become valuable diagnostic
and prognostic markers as well as potential therapeutic targets for
pancreatic cancer (110). Moreover, immunohistochemistry result
suggested the expressions of GLI1, DNMT1, and DNMT3a in pan-
creatic cancer tissues were higher than those in adjacent normal
tissues. DNMT1 and DNMT3a are regulated by GLI1 in pancreatic
cancer (47).
BREAST CANCER
Breast cancer is the most common form of cancer diagnosed
in women worldwide, accounting for 23% (1.38 million) of the
total new cancer cases and 14% of the cancer deaths in 2008
(111, 112). Although the rate of mortality as a result of breast
cancer has decreased in western countries, including the USA,
in part due to early detection. ACS estimates that 235,030 new
breast cancer cases will be identified in the United States in 2014
with an estimated death rate of 40,430 (15%) (60, 62). Breast
cancer has a heterogeneous predisposition at both the histologi-
cal and molecular levels. At least six distinct subtypes have been
described on the basis of gene expression profiling, with the most
important determinants of these subtypes being the presence or
absence of expression of the estrogen or progesterone receptor or
the amplification/overexpression of the HER2/ERBB2 locus (113).
Subgroups of breast cancer are frequently distinguished into lumi-
nal A (estrogen/progesterone-positive), luminal B, HER2+, and
so-called “triple negative” subtypes (114). Despite the ability of
these subtypes to predict outcome, patient response to chemother-
apy or targeted therapy remains variable. The current standard of
therapy for breast cancer includes surgical resection, radiation,
and chemotherapeutic agents such as cisplatin, pacliataxel, carbo-
platin, bevacizumab, doxorubicin, cyclophosphamide, docetaxel,
and epirubicin (115).
Our understanding of CSCs comes primarily from studies
on breast cancer stem cells (BrCSC). These have been isolated
from human breast tumors or breast cancer-derived pleural effu-
sions using flow cytometry for a specific pattern of cell surface
marker expression (CD44+, CD24−/low, and ESA+) (116–118).
Many groups have attempted to confirm that the minimum sur-
face phenotype for a tumorigenic BrCSC is CD44+CD24− (119).
In addition, CD133 (also a marker of CSC population in other
tumors) and in some cases, selected members of the integrin family
of receptors (beta1, alpha6, or beta3 integrins), alone or in con-
junction with the CD44+/CD24− phenotype have also been used
to isolate the BrCSCs (120). Aldehyde dehydrogenase (ALDH)
expression has similarly been used as a marker for BrCSCs (121).
While these markers have exciting implications, it remains to be
seen whether a single cell isolated by this method can develop new
tumors in animal models.
BREAST CANCER AND DNMTs
In cancer, DNMTs are overexpressed in various tumor types,
including breast cancer (28, 52, 122). Surprisingly, the mean levels
of DNMT1, DNMT3a, and DNMT3b overexpression have turned
out to be quite similar among different tumor types. The DNMT3b
gene has shown the highest range of expression (81.8 for DNMT3a
compared with 16.6 and 14 for DNMT1 and DNMT3a, respec-
tively). In breast cancer, ~30% of patients revealed overexpression
of DNMT3b in the tumor tissue as compared to normal breast
tissue. Taking only these overexpressing tumors into account,
the DNMT3b expression change was 82-fold, thus being signif-
icantly higher (28). Interestingly, DNMT1 and DNMT3a were
overexpressed in only 5 and 3% of breast carcinomas (52). Thus,
DNMT3b plays the predominant role over DNMT3a and DNMT1
in breast tumorigenesis. This is consistent with a recent study in
breast cancer cell lines, which demonstrated a strong correlation
between total DNMT activity and overexpression of DNMT3b,
but not with the expression of DNMT3a or DNMT1 (52).
ROLE OF DNMT’s IN OTHER CANCERS
One study with prostate cancers demonstrated that the activ-
ity of DNMT1, DNMT3a, and DNMT3b are twofold to three-
fold higher in cancer cell lines and cancer tissues, as compared
with a benign prostate epithelium cell line and benign prostatic
hyperplasia tissues (27). Similarly, in a study with kidney cancer,
expression of DNMT1 was higher in the carcinoma tissue com-
pared to the adjacent normal tissue (123). DNMT1 and DNMT3b
were also observed to be up to threefold higher in ovarian can-
cer cells than in normal ovarian surface epithelial cells (124,
125). Similarly, in hepatocellular carcinomas, there is increased
expression of DNMT1, DNMT3a, and DNMT3b and a progres-
sive increase in the number of methylated genes from normal
liver, chronic hepatitis/cirrhosis to hepatocellular carcinoma. Fur-
thermore, increase in the DNMT3a and DNMT3b mRNA in the
carcinoma tissues relative to their non-cancerous normal may be a
predictor of poor survival (30). Moreover, Mutze et al. had shown
that DNMT1 is a predictive biomarker and potential therapeutic
target for chemotherapy in gastric cancer (126). Another study
demonstrated that DNMT1 and DNMT3b are overexpressed in
gliomas (48).
Similarly in acute myelogenous leukemias, DNMT1, DNMT3a,
and DNMT3b levels were significantly upregulated when com-
pared to control bone marrow cells. Although CML cells in
the chronic phase did not show significant changes, cells in the
acute phase also showed increased levels of the three DNMTs.
Frontiers in Oncology | Cancer Molecular Targets and Therapeutics May 2014 | Volume 4 | Article 80 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subramaniam et al. DNA methyltransferases and cancer
These data suggest that upregulated DNMTs may contribute
to the pathogenesis of leukemia by inducing aberrant regional
hypermethylation (44).
LACUNAS IN THE DNMT’s RESEARCH IN CANCER BIOLOGY
DNMT2 or TRDMT1 and DNMT3L are yet to be studied in
detail in the different cancers. DNMT2 was shown to methylate
tRNA (15, 127, 128). DNMT2 levels were found to be signif-
icantly lower in colorectal and stomach cancers than in non-
cancerous tissue (50). In addition, significant overexpression of
DNMT3b and reduced expression of DNMT2 were observed in
hepatocellular carcinomas compared with the corresponding non-
cancerous liver tissues (49). DNMT2 utilizes a DNMT mechanism
for RNA methylation (129). DNMT2 activity can be monitored
by tRNAAsp methylation analysis and has been identified as a
promising candidate biomarker for azacytidine therapy (129, 130).
DNMT3L is essential for the establishment of maternal
genomic imprints but lacks key methyltransferase motifs and is
possibly a regulator of methylation rather than an enzyme that
methylates DNA (128, 131). Gokul et al. revealed that significant
DNA methylation differences within the promoter of DNMT3L. A
regulator of de novo DNMTs, DNMT3a and DNMT3b, DNMT3L
promoter was found to have lost DNA methylation to varying lev-
els in 14 out of 15 cancer cervix samples that were analyzed. This
study highlights the importance of DNA methylation profile at
DNMT3L promoter as a promising biomarker for cervical cancer
and provides insight into the possible role of DNMT3L in cancer
development (55). Another study demonstrated that DNMT3L is
a novel marker and was essential for the growth of human embry-
onal carcinoma (56). Additional studies are required for the precise
role for DNMT3L on other cancers.
DNMTs PROMOTE CANCER
Three DNMTs encoded by different genes are known to partici-
pate in generating and maintaining the DNA methylation pattern:
DNMT1 (132), DNMT3a, and DNMT3b (133). Several studies
have shown that DNMT1 is particularly involved in controlling
cell growth (134, 135). Chik and Szyf determined whether specific
inhibition of DNMT1 would increase the selectivity toward inhi-
bition of cellular transformation and reduce the risk of increasing
cell invasiveness. They found that depletion of DNMT1 had the
strongest effect on colony growth suppression in cellular transfor-
mation but did not induce cellular invasion in MCF-7 and ZR-75-1
non-invasive breast cancer cell lines (136). Studies have also shown
that overexpression of DNMT1 in non-transformed cells leads
to cellular transformation (34), whereas knockout of DNMT1
protects mice from colorectal cancer (80). In addition, targeted
deregulation of DNMTs by hepatitis B virus X protein promotes
both specific regional hypermethylation and global hypomethy-
lation. These epigenetic modulations by hepatitis B virus X pro-
tein may suggest a mechanism for epigenetic tumorigenesis dur-
ing HBV-mediated hepatocarcinogenesis (137). Moreover, recent
study demonstrated that interleukin (IL)-23, was shown to induce
DNMT1 in a STAT5-dependent manner (138).
INHIBITION OF DNMTs FOR ANTI-CANCER THERAPY
Inhibition of DNMTs correlates with reduction in tumorigenicity
and increased expression of tumor suppressor genes (139). Hence,
DNMTs are considered valuable targets for the design of specific
anti-cancer strategies. The three most commonly used catalytic
inhibitors of DNMTs are the nucleoside analogs 5-azaC, 5-azaCdR,
and zebularine. The mechanism of action of these three inhibitors
is unique. These agents are pro-drugs that need to be incorpo-
rated into DNA to act as inhibitors of DNMTs. The nucleoside
analogs are first phosphorylated to the triphosphate nucleotide
and incorporated into DNA during DNA synthesis. DNMT1 forms
a covalent bond with the carbon at position 6 of the cytosine as
well as 5-aza-cytosine ring. Under normal conditions the enzyme
transfers the methyl group from SAM to the fifth carbon position
of the cytosine ring. This enables the release of the enzyme from its
covalent bond with cytosine. When a 5′-aza-cytosine ring replaces
cytosine in the DNA, the methyl transfer does not take place and
the DNMT is trapped on the DNA (140). The replication fork pro-
gresses in the absence of DNMT1 resulting in passive loss of DNA
methylation in the nascent strand but not the template. Zebular-
ine is a nucleoside analog, which unlike 5-azaC is chemically stable
and is orally bioavailable. Zebularine has been originally identi-
fied as a cytidine deaminase inhibitor (128, 141). Decitabine and
5-azacytidine are two well-known inhibitors of DNMTs that are
effective against bone marrow disorders such as myelodysplastic
syndrome (142). There are several DNMTs inhibitors that were
studied in several cancers and these are summarized in Table 2.
CHEMOPREVENTIVE AGENTS AND DNMTs
To prevent, the onset of cancer, the National Institutes of Health
(NIH) in the United States recommended a high fiber, low fat diet,
consisting of more fruits and vegetables. Epidemiological studies
suggest that diet plays a major role in the prevention of many
cancers. The inhibitory effect of chemopreventive compounds on
various DNMTs is shown in Figure 2.
Black Raspberry-derived anthocyanins were first shown to
inhibit DNMT1 and DNMT3B in colon cancer cells. Oral admin-
istration of black raspberry powder (BRP) decreased promoter
methylation of tumor suppressor genes in tumors from patients
with colorectal cancer. The anthocyanins in black raspberries are
responsible, at least in part, for their cancer-inhibitory effects.
Three days of treatment with anthocyanins suppressed both
expression and activity of DNMT1 and DNMT3B proteins in
HCT116, Caco2, and SW480 cells. Promoters of CDKN2A, and
SFRP2, SFRP5, and of WIF1, an inhibitor of the Wnt pathway, were
demethylated by anthocyanins. Moreover, expression of β-catenin
and c-Myc mRNA, downstream of Wnt pathway were decreased
resulting in reduced cell proliferation and increased apoptosis.
Anthocyanins were taken up into HCT116 cells and were differ-
entially localized with DNMT1 and DNMT3B in the same cells
visualized using confocal laser scanning microscopy. Although a
previous study reported that DNMT3B is regulated by c-Myc in
mouse lymphoma, DNMT3B did not bind with c-Myc in HCT116
cells. These findings suggest that anthocyanins are responsible, at
least in part, for the demethylation effects of whole black rasp-
berries in colorectal cancers (155). In another study, the biopsies
of adjacent normal tissues and colorectal adenocarcinomas were
taken from 20 patients before and after oral consumption of BRP
(60 g/day) for 1–9 weeks. Methylation status of promoter regions
of five tumor suppressor genes was quantified. Protein expression
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Table 2 | Available DNMT in inhibitors and cancer.
DNMT inhibitors Dose range Clinical trials Reference
5-Azacytine µM Phase I, II, III: hematological malignancies Kaminskas et al. (143), Yoo and Jones (144)
5-Aza-2′-deoxycytidine µM Phase I, II, III: hematological malignancies;
cervical, non-small-cell lung cancer
Yoo and Jones (144), Prakash et al. (145), Pauer et al. (146)
5-Fluoro-2′-deoxycytidine µM Phase I Yoo and Jones (144), Eidinoff and Rich (147)
5,6-Dihydro-5-azacytidine µM Phase I, II: ovarian cancer and lymphomas Yoo and Jones (144), Curt et al. (148)
Zebularine µM–mM Cheng et al. (141), Yoo and Jones (144), Holleran et al. (149)
Hydralazine Phase I: cervical cancer Yoo and Jones (144), Zambrano et al. (150)
Procainamide Preclinical Yoo and Jones (144), Chuang et al. (151)
EGCG Preclinical Yoo and Jones (144), Fang et al. (152)
RG108 Preclinical Yoo and Jones (144), Brueckner et al. (153)
SGI-110 Phase II: AML Gros et al. (154)
FIGURE 2 | Chemopreventive agents and DNMTs.
of DNMT1 and genes associated with cell proliferation, apopto-
sis, angiogenesis, and Wnt signaling were measured. They found
that the methylation of three Wnt pathway inhibitors, SFRP2,
SFRP5, and WIF1, and PAX6a, a developmental regulator, was
modulated in a protective direction by BRBs in normal tissues and
in colorectal tumors. Moreover, this effect was only observed in
patients who received BRB treatment for an average of 4 weeks,
but not in the 20 patients who received treatment for 1–9 weeks.
This was associated with decreased expression of DNMT1. BRBs
modulated expression of genes associated with Wnt pathway, pro-
liferation, apoptosis, and angiogenesis in a protective direction.
Their data provide evidence of the ability of BRBs to demethy-
late tumor suppressor genes and to modulate other biomarkers of
tumor development in the human colon and rectum (156).
Annurca apple is an apple variety from southern Italy that is
rich in polyphenols. Annurca apple polyphenol extracts inhib-
ited the expression of DNMT1 and DNMT3b in colon can-
cer cells (157). Furthermore, a recent study demonstrated that
acetyl-keto-β-boswellic acid, derived from the plant Boswellia ser-
rata, an Indian frankincense inhibits DNMT activity in colorectal
cancer cell lines (158). Most recently, the flavonolignan silibinin,
which is the main pharmacologically active component of the
milk thistle plant (Silybum marianum) with anti-cancer proper-
ties is able to significantly inhibit DNMT activity in colon cancer
cells (159).
Green tea has also been shown to modulate DNMT activ-
ity to inhibit tumorigenesis. EGCG, the major polyphenol in
green tea, has many interesting activities and is believed to be
a key active ingredient. It dose-dependently inhibited DNMT
activity, showing competitive inhibition with a Ki of 6.89µM in
human esophageal squamous cell carcinoma cell lines (152, 160).
Moreover, a breast cancer study demonstrated that tea polyphe-
nols [catechin, epicatechin, and (−)-epigallocatechin-3-O-gallate
(EGCG)] and bioflavonoids (quercetin, fisetin, and myricetin)
inhibited DNMT1-mediated DNA methylation in a dose depen-
dent manner. The IC50 values for catechin, epicatechin, and
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various flavonoids ranged from 1.0 to 8.4µM, but EGCG was
a more potent inhibitor, with IC50 values ranging from 0.21
to 0.47µM in MCF-7 and MDA-MB-231 cell lines (161, 162).
Similarly, genistein present in soybean modulates enzymes that
regulate DNA methylation and reactivates tumor suppressor genes
in esophageal cancer cells (163, 164). Furthermore, two common
catechol-containing coffee polyphenols such as caffeic acid and
chlorogenic acid inhibits DNMT1 levels in breast cancer cells.
The IC50 values of caffeic acid and chlorogenic acid were 3.0
and 0.75µM, respectively (161). Curcumin, the active ingredient
in turmeric has also been shown to affect DNMT activity. Vir-
tual screening using a DNMT1 homology model suggested two
binding modes for curcumin in the catalytic domain. Experimen-
tal inhibition of the bacterial C5 DNMT M. SssI confirmed that
curcumin and derivatives can inhibit the protein with IC50 val-
ues around 30 nM. Curcumin at doses higher than 3 mM also
induced a decrease of global DNA demethylation of leukemia
MV4-11 cells (154, 165). Furthermore, a recent study demon-
strated that curcumin down-regulates DNMT1 expression in AML
cell lines, both in vitro and in vivo, and in primary AML cells ex
vivo (166).
Thymus serpyllum (wild thyme) is an aromatic medicinal plant
possessing several biological properties including anti-cancer
activity. T. serpyllum extract induced significant cytotoxicity in
breast cancer cells (MCF-7 and MDA-MB-231) but not in nor-
mal cells. It also induced apoptosis and inhibited the DNMT and
HDAC activities in MDA-MB-231 cells (167). Recently, an iden-
tification of Kazinol Q, a natural product from formosan plants,
was found to act as an inhibitor of DNMTs (168). In addition, a
more recent study demonstrated that natural compounds such as
EGCG, genistein, withaferin A, curcumin, resveratrol, and guggul-
sterone inhibit DNMT1, DNMT3a, and DNMT3b expression in
breast cancer cell lines (169).
CONCLUSION
The cancer stem cell hypothesis is gaining acceptance after the
accumulation of extensive research evidence suggesting that the
small subset of the tumor mass is responsible for the sustained
growth of the tumor. Furthermore, it is becoming apparent that
the cancer stem cells are responsible for disease relapse and resis-
tance to the existing therapies. DMNTs have also upregulated
in various cancers including colon, pancreatic, and breast can-
cers and their stem cells. Current DNMT inhibitors such as
Decitabine and 5-azacytidine have adverse side effects. Identify-
ing new drugs that can specifically target DNMTs and also cancer
stem cells could lead to a new generation of anti-cancer med-
icines and with it, a new strategy for treatment. For instance,
dietary phytochemicals are natural products found in our diet
and can be used to target cancer stem cells. Thus, identification
of such cancer stem cell targeting therapy and their use in combi-
nation with standard DNMT inhibitors will curtail this dreadful
disease.
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